# Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

> **NCT00144222** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 218 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan 40 mg/HCTZ 12.5 mg
- **DRUG:** Telmisartan 40 mg

## Key facts

- **NCT ID:** NCT00144222
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2013-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144222, "Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00144222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*